Who are Theragenepharma's investors?

Theragenepharma's investors include Thynk Capital.

How much funding has Theragenepharma raised?

Theragenepharma has disclosed $548K raised across 2 rounds.

Where is Theragenepharma headquartered?

Theragenepharma is headquartered in San Diego, US.

Theragenepharma

San Diego, US · Founded 2011 · 1 known investors

Theragene Pharmaceuticals develops immunotherapy and gene therapy treatments for cancer and cardiovascular diseases using AAV technology. The company operates in the US and Asia, pursuing partnerships for product development and licensing.

BiotechDigital HealthMedical Devices

Founders & leadership

Jon BerglinExecutive

Board

Steven DavisBoard director

Daniel CouryBoard director

Chaojie ZhangBoard director

Investors · 1

Thynk Capitalvia Jim Plante · inferred

Reported raises · per SEC filings

Form D private placements

$548K disclosed across 2 rounds · 2014–2015

▶$200KraisedAug 2015 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steven DavisDirector
Daniel CouryDirector
Chaojie ZhangDirector
Jon BerglinExecutive Officer, Director

Offering amount: $30M
Amount sold: $200K
Minimum investment: $200K
Proceeds to insiders: $1.5M
First sale: Jul 2015
Incorporated: Corporation, California, 2011
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$348KraisedMar 2014 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Chaojie ZhangDirector
Steven DavisDirector
Daniel CouryDirector
Jon BerglinExecutive Officer, Director

Offering amount: $2M
Amount sold: $348K
Minimum investment: $5K
First sale: Feb 2014
Incorporated: Corporation, California, 2011
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Allogene9 shared keywordsAllogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches. The company aims to expand CAR T treatment access through scalable manufacturing, lower costs, and faster treatment delivery.

enGene8 shared keywordsenGene develops detalimogene voraplasmid (formerly EG-70), a non-viral gene therapy in clinical development to treat non-muscle invasive bladder cancer (NMIBC). The therapy is being studied in the pivotal LEGEND clinical trial.

Companies competing with Theragenepharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Theragenepharma do?: Theragene Pharmaceuticals develops immunotherapy and gene therapy treatments for cancer and cardiovascular diseases using AAV technology. The company operates in the US and Asia, pursuing partnerships for product development and licensing.
Who are Theragenepharma's investors?: Theragenepharma's investors include Thynk Capital.
How much funding has Theragenepharma raised?: Theragenepharma has disclosed $548K raised across 2 rounds.
Where is Theragenepharma headquartered?: Theragenepharma is headquartered in San Diego, US.